Y23 Stock Overview
Through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akanda Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.30 |
| 52 Week High | US$34.00 |
| 52 Week Low | US$2.30 |
| Beta | 1.59 |
| 1 Month Change | -51.95% |
| 3 Month Change | -68.02% |
| 1 Year Change | -91.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| Y23 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -34.2% | 0.3% | -0.7% |
| 1Y | -91.3% | -18.9% | 4.7% |
Return vs Industry: Y23 underperformed the German Pharmaceuticals industry which returned -18.9% over the past year.
Return vs Market: Y23 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| Y23 volatility | |
|---|---|
| Y23 Average Weekly Movement | 56.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: Y23's share price has been volatile over the past 3 months.
Volatility Over Time: Y23's weekly volatility has increased from 43% to 57% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Katie Field | www.akandacorp.com |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Akanda Corp. Fundamentals Summary
| Y23 fundamental statistics | |
|---|---|
| Market cap | €4.67m |
| Earnings (TTM) | -€29.71m |
| Revenue (TTM) | €1.99m |
2.4x
P/S Ratio-0.2x
P/E RatioIs Y23 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Y23 income statement (TTM) | |
|---|---|
| Revenue | US$2.16m |
| Cost of Revenue | US$2.05m |
| Gross Profit | US$111.45k |
| Other Expenses | US$32.39m |
| Earnings | -US$32.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.84 |
| Gross Margin | 5.16% |
| Net Profit Margin | -1,494.18% |
| Debt/Equity Ratio | -100.9% |
How did Y23 perform over the long term?
See historical performance and comparison